Statin Labeling Changes Include Class Warning About Glucose Effects
This article was originally published in The Pink Sheet Daily
All statin labels now warn that “increases in HbA1C and fasting serum glucose levels have been reported” with the cholesterol-lowering drugs. Labels also reflect a relaxation of hepatic monitoring requirements, which could remove one hurdle to Pfizer’s pursuit of an OTC switch for Lipitor.
You may also be interested in...
Emerging data on the hotly anticipated PCSK9 inhibitor class show unprecedented declines in LDL cholesterol levels and no signs of the safety issues that plague statins – including myalgia and neurocognitive events.
The sponsors of the PCSK9 inhibitor class are getting lots of data boxes ticked off with the results presented at the American College of Cardiology, but it’s still largely a waiting game as investors, practitioners and patients wait for regulatory submissions and outcomes trials. New details on doses and devices preview commercial battle between Amgen’s evolocumab and Sanofi/Regeneron’s alirocumab.
In shifting away from specific targets and non-statin add-on therapies, new ACC/AHA cholesterol guidelines support treatment of people at relatively low risk for events and more intensive therapy for those at higher risk.